What is it about?

This is the first study to examine Glasgow Prognostic Score (GPS) subgroups among patients with advanced non-small-cell lung cancer and poor performance status (>=2), and we observed several key results. First, the malnourished group (GPS 2) was less able to tolerate platinum combination chemotherapy than the well-nourished group (GPS 0-1). Second, the malnourished group had a shorter progression-free survival and lower response rate than the well-nourished group. Third, the malnourished group had shorter overall survival than the well-nourished group.

Featured Image

Why is it important?

Malnutrition (defined as GPS of 2) decreases the tolerability and efficacy of platinum combination chemotherapy for patients with advanced non-small cell lung cancer and poor performance status (>=2). GPS reflects systemic inflammation and malnutrition, and may be associated with cachexia, which might explain the relationship with worse oncological outcomes.

Perspectives

Patients with poor PS remain challenging to treat. The risks and benefits of chemotherapy should be carefully evaluated before decision making in this population.

MD. PhD. Tateaki Naito
Shizuoka Cancer Center

Read the Original

This page is a summary of: Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status, Nutrition and Cancer, January 2019, Taylor & Francis, DOI: 10.1080/01635581.2018.1559941.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page